KR101835263B1 - Composition having antimicrobial activities for prevention and treatment of urinary tract infection - Google Patents
Composition having antimicrobial activities for prevention and treatment of urinary tract infection Download PDFInfo
- Publication number
- KR101835263B1 KR101835263B1 KR1020170017341A KR20170017341A KR101835263B1 KR 101835263 B1 KR101835263 B1 KR 101835263B1 KR 1020170017341 A KR1020170017341 A KR 1020170017341A KR 20170017341 A KR20170017341 A KR 20170017341A KR 101835263 B1 KR101835263 B1 KR 101835263B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- urinary tract
- weight
- chain fatty
- parts
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 208000019206 urinary tract infection Diseases 0.000 title claims abstract description 37
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 28
- 238000011282 treatment Methods 0.000 title description 9
- 230000002265 prevention Effects 0.000 title description 2
- 241000588724 Escherichia coli Species 0.000 claims abstract description 30
- 239000000341 volatile oil Substances 0.000 claims abstract description 26
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 15
- 239000000194 fatty acid Substances 0.000 claims abstract description 15
- 229930195729 fatty acid Natural products 0.000 claims abstract description 15
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 15
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 10
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 35
- 235000004634 cranberry Nutrition 0.000 claims description 35
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 34
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 34
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 24
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 17
- 229960002446 octanoic acid Drugs 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000003674 animal food additive Substances 0.000 claims description 14
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 14
- 239000005844 Thymol Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 229960000790 thymol Drugs 0.000 claims description 10
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 2
- 244000291414 Vaccinium oxycoccus Species 0.000 claims 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 abstract description 21
- 208000015181 infectious disease Diseases 0.000 abstract description 14
- 230000002458 infectious effect Effects 0.000 abstract description 13
- 239000004615 ingredient Substances 0.000 abstract description 6
- 230000009467 reduction Effects 0.000 abstract description 3
- 235000012511 Vaccinium Nutrition 0.000 abstract 1
- 241000736767 Vaccinium Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 39
- 239000000243 solution Substances 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 13
- 230000036541 health Effects 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- -1 bacteriostats Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000005445 natural material Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HVTQDSGGHBWVTR-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-phenylmethoxypyrazol-1-yl]-1-morpholin-4-ylethanone Chemical compound C(C1=CC=CC=C1)OC1=NN(C=C1C=1C=NC(=NC=1)NC1CC2=CC=CC=C2C1)CC(=O)N1CCOCC1 HVTQDSGGHBWVTR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000025053 Escherichia coli DSM 30083 = JCM 1649 = ATCC 11775 Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001084338 Listeria sp. Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000607149 Salmonella sp. Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019463 artificial additive Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000021019 cranberries Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000021579 juice concentrates Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- LWJKSVUJZBEXCH-UHFFFAOYSA-N n-[5-[2-chloro-5-(trifluoromethyl)phenyl]pyrazin-2-yl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CN=C(C=2C(=CC=C(C=2)C(F)(F)F)Cl)C=N1 LWJKSVUJZBEXCH-UHFFFAOYSA-N 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
본 발명은 크랜베리 용액, 중쇄 지방산 및 에센셜 오일을 포함하는 요로병원성 대장균의 항균용 조성물에 관한 것이다.The present invention relates to a composition for antibacterial activity of urinary tract pathogenic Escherichia coli comprising a cranberry solution, a medium chain fatty acid and an essential oil.
요로감염증은 요도, 방광, 요관, 콩팥 등 요로기계의 감염을 통칭하는 질병으로, 전 세계 40% 이상의 여성들은 일생동안 한 번은 이 질병을 경험하게 된다. 요로감염은 다양한 장내 세균에 의해 발생하는데 이 중 80% 이상의 원인이 되는 균주는 Escherichia coli 종이다. 이들 균주들은 요로에 부착되어 염증을 일으키는 기작으로 요로감염증을 유발하는데, 심한 경우 바이오필름을 형성하여 재발성 요로감염증을 일으키게 된다.Urinary tract infection is a disease that refers to the infection of the urinary tract such as urethra, bladder, ureter and kidney. More than 40% of women around the world experience this disease once in their lifetime. Urinary tract infections are caused by various intestinal bacteria, of which more than 80% are caused by Escherichia lt; / RTI > These strains attach to the urinary tract and cause inflammation, leading to urinary tract infections. In severe cases, they form biofilms and cause recurrent urinary tract infections.
현재 요로감염증을 예방하고 치료하기 위해 사용되는 방법으로는 항생제 치료법과 위생용품(청결제, 세척제 등)의 사용 등을 들 수 있다. 하지만 항생제 치료법의 경우에는 면역력이 약한 개인이나 환자에게는 사용할 수 없고 항생제 내성균이 생길 수 있다는 단점을 가진다. 반면 위생용품을 사용하는 방법은 항생제와 같은 약물에 의한 치료를 기피하고 예방적인 질병 대처를 선호하는 소비자의 인식을 반영한 요로감염증 예방 및 치료 방법으로 관심을 받고 있다.Methods currently used to prevent and treat urinary tract infections include antibiotic treatment and use of sanitary products (such as cleansers and cleansers). However, in the case of antibiotic therapy, it can not be used in individuals or patients with weak immunity, and it has disadvantages that antibiotic resistant bacteria can be produced. On the other hand, the use of hygienic products is attracting attention as a method of preventing and treating urinary tract infections, which reflects consumers' preference to avoid preventive diseases by avoiding medication such as antibiotics.
크랜베리(Vaccinium macrocarpon)는 높은 비타민C 함량을 갖는 과일로, 특유의 상큼한 맛과 높은 항산화 작용 등의 건강상 이점으로 전 세계적으로 높은 인기를 끌고 있다. 또한 이는 요로감염증을 제어하는 여러 기작을 가져 이의 예방 및 치료를 위해 식이요법으로도 많이 이용된다. 대표적인 제어기작으로는 당과 유기산 성분으로 요로감염균의 삼투 스트레스를 유발하는 기작과 안토시아닌류로 요로감염균의 외막을 분해하는 기작을 들 수 있다. 특히, 크랜베리에 함유된 안토시아닌류의 경우에는 요로에서 요로감염균의 부착을 방지하고 탈착을 촉진하는 기작을 통해 요로감염증을 예방한다는 연구결과가 다수 존재하고는 있지만(특허문헌 1 및 2), 현실적으로 요로감염증 치료를 위해 사용되기에는 그 치료 효과가 미미한 수준이다.Cranberry ( Vaccinium macrocarpon ) is a fruit with a high vitamin C content and has gained worldwide popularity due to its health benefits such as its unique fresh taste and high antioxidant activity. It also has many mechanisms to control urinary tract infections and is often used as a diet for the prevention and treatment of urinary tract infections. Typical control mechanisms include the mechanism of inducing osmotic stress of urinary tract infection by sugar and organic acid components and the mechanism of decomposing the outer membrane of urinary tract infection with anthocyanins. In particular, in the case of anthocyanins contained in cranberries, there are many studies that prevent urinary tract infections by preventing adherence of urinary tract infections in the urinary tract and promoting desorption (Patent Documents 1 and 2) Its therapeutic effect is insignificant to be used for the treatment of infectious diseases.
한편, 천연물질에 대한 소비자의 요구가 증가함에 따라 자연에서 유래한 식품 및 의료용 첨가물질이 인기를 얻고 있다. 이 중 중쇄 지방산과 에센셜 오일은 천연 유래 물질로써 다양한 세균(바실러스 속 균, 대장균, 장출혈성 대장균 O157:H7, 리스테리아 속 균, 살모넬라 속 균, 황색포도상구균, 시겔라 속 균 등)에 대한 항균작용이 널리 알려져 있다. 이들은 자연에서 유래했다는 점과 식품 및 의료·보건 분야의 첨가물로써 인정을 받고 있고 있다는 점 때문에 천연보존제로서 소비자들에게 거부감 없이 받아들여진다. 다만, 천연 물질이므로 합성 첨가물보다는 경제적인 부담이 존재하기 때문에 조합처리를 이용한 효율적 제어기술 개발이 요구되고 있다.On the other hand, as consumers' demand for natural materials increases, natural and food additive materials are gaining popularity. Among these, the heavy-chain fatty acids and essential oils are naturally derived substances and have antibacterial activity against various bacteria (Bacillus sp., Escherichia coli, E. coli O157: H7, Listeria sp., Salmonella sp., Staphylococcus aureus, This is widely known. They are accepted as consumers of natural preservatives because they are derived from nature and are recognized as additives in the food, medical and health sectors. However, since it is a natural substance, there is an economic burden rather than a synthetic additive, so it is required to develop an efficient control technique using a combination treatment.
이에, 천연 물질을 이용하여 크랜베리의 항균 능력을 증진시켜 요로감염증을 효과적으로 예방, 개선 또는 치료할 수 있는 조성물의 개발이 필요한 실정이다.Accordingly, there is a need to develop a composition capable of effectively preventing, ameliorating, or treating urinary tract infections by enhancing the antibacterial ability of cranberry using a natural substance.
본 발명의 목적은 천연 물질의 조합에 따른 항균 시너지 효과를 이용하여 요로감염성 대장균의 바이오필름을 제거함으로써 요로감염증 예방 및 치료를 위한 조성물을 제공하는 것이다.It is an object of the present invention to provide a composition for preventing and treating urinary tract infections by removing the biofilm of urinary tract infectious Escherichia coli by utilizing the antimicrobial synergistic effect according to the combination of natural substances.
본 발명자들은 요로감염증을 예방하기 위한 항균용 조성물에 대하여 천연물을 대상으로 연구를 진행하던 중 항균 시너지를 일으키는 천연 성분들의 조합 및 그 비율을 탐색하여 항균 시너지를 극대화할 수 있음을 확인하고 본 발명을 완성하였다.The inventors of the present invention confirmed that the antimicrobial composition for preventing urinary tract infections can maximize the antimicrobial synergy by searching for the combination of the natural components causing the antimicrobial synergy and the ratio thereof during the research on natural products, Completed.
본 발명은 크랜베리 용액; 중쇄 지방산으로서의 카프릴산; 및 에센셜 오일로서 타임 티몰을 유효성분으로 포함하는 요로감염성 대장균에 대한 항균용 조성물, 상기 항균용 조성물을 포함하는 약학 조성물, 식품 조성물, 사료 또는 사료 첨가제 조성물, 위생용품 및 요로감염성 대장균의 활성 억제 방법을 제공한다.The present invention relates to a cranberry solution; Caprylic acid as a medium chain fatty acid; And antimicrobial composition for urinary tract infectious Escherichia coli containing timothymol as an essential oil as an essential oil, a pharmaceutical composition comprising the antimicrobial composition, a food composition, a feed or feed additive composition, a method for inhibiting the activity of a sanitary article and a urinary infectious Escherichia coli .
하기 실시예에서는, 크랜베리 용액, 카프릴산 및 타임 티몰을 조합하여 그 비율에 따른 조성물의 요로감염성 대장균에 대한 항균활성을 확인하였으며, 상기 성분들의 조합에 의한 항균 시너지로부터 개별적으로 사용되는 크랜베리 용액, 카프릴산 및 타임 티몰의 양을 최소화할 수 있음을 확인하였다. 따라서, 일정 비율로 조합된 크랜베리 용액, 카프릴산 및 타임 티몰은 요로감염성 대장균에 대한 항균용 조성물의 유효성분으로서 사용될 수 있다.In the following Examples, cranberry solution, caprylic acid and time thymol were combined to confirm the antimicrobial activity of the composition against urinary tract infectious Escherichia coli, and the cranberry solution, Caprylic acid and time-thymol can be minimized. Therefore, cranberry solution, caprylic acid, and time thymol combined at a certain ratio can be used as an active ingredient of a composition for antibiosis against urinary tract infectious Escherichia coli.
이하, 본 발명의 구성을 상세히 설명한다.Hereinafter, the configuration of the present invention will be described in detail.
본 발명은 크랜베리 용액; 중쇄 지방산으로서 카프릴산; 및 에센셜 오일로서 타임 티몰을 포함하는 요로감염성 대장균에 대한 항균용 조성물을 제공한다.The present invention relates to a cranberry solution; Caprylic acid as a medium chain fatty acid; And antimicrobial composition against urinary tract infectious Escherichia coli including time thymol as an essential oil.
본 발명에 있어서, "중쇄 지방산"이란 탄소수가 8 내지 12개이고 이중결합이 없는 지방산으로, 첨가물공전 등재번호가 192번인 카프릴산(Caprylic acid)를 말한다. In the present invention, the term "heavy chain fatty acid" refers to caprylic acid having 8 to 12 carbon atoms and a double bond-free fatty acid,
본 발명에 있어서, "에센셜 오일(essential oil, 정유)"이란 타임 티몰로부터 향기 성분을 응축하여 얻은 오일상의 추출물을 말한다. 상기 에센셜 오일의 제조에는 수증기 증류법, 휘발성 용제(벤젠, 헥산 등)를 이용한 용제 추출법, 침출법(추출 대상에 상처를 내어 침출 수액을 수집하는 방법), 압착법, 초임계 추출법 등을 이용할 수 있으나, 이에 제한되는 것은 아니며 당업계에 공지된 방법을 이용하여 제조할 수 있다. 또한, 상기 에센셜 오일은 시판되는 제품을 이용할 수 있다.In the present invention, "essential oil" refers to an oil-phase extract obtained by condensing fragrance components from timothymol. The essential oil can be prepared by a steam distillation method, a solvent extraction method using a volatile solvent (benzene, hexane, etc.), a leaching method (a method of collecting leachate by scratching the extraction target), a pressing method, a supercritical extraction method, , But it is not limited thereto and can be produced by using methods known in the art. In addition, commercially available products can be used as the above essential oils.
본 발명에 있어서, 상기 항균용 조성물은 요로감염성 대장균에 대한 항균 활성을 나타낸다. In the present invention, the antimicrobial composition exhibits antibacterial activity against urinary tract infectious Escherichia coli.
상기 요로감염성 대장균(uropathogenic Escherichia coli)은 요로 벽에 부착하여 응집하며, 체내 점막 장벽을 뚫고 들어가는 등 여러 독성 요인을 가지고 있어 일반적인 방법으로 살균하기 어려운 병원균 중 하나에 속한다. 상기 요로감염성 대장균에 의해 유발되는 요로감염증으로는 요도염, 방광염, 요관염, 신우신염 등이 있고, 이에 제한되는 것은 아니며 요로 중 감염된 기관에 따라 질병명이 달라질 수 있다.The Uropathogenic Escherichia Coli is one of the pathogens that are difficult to sterilize by common methods because they have many toxic factors such as sticking to the urinary tract wall and coagulating and penetrating mucosal barrier in the body. Urinary tract infections caused by the urinary tract infectious Escherichia coli include urethritis, cystitis, urethritis, pyelonephritis, and the like, but the present invention is not limited thereto.
따라서, 본 발명에 따른 조성물은 상기 요로감염성 대장균의 활성을 억제함으로써 요로감염성 대장균에 의한 요도감염증을 예방, 개선 또는 치료할 수 있다.Therefore, the composition according to the present invention can prevent, ameliorate, or treat the urinary tract infection caused by urinary tract infectious Escherichia coli by inhibiting the activity of the urinary tract infectious Escherichia coli.
본 발명에 있어서, 크랜베리 용액은 전체 조성물 100 중량부에 대해 크랜베리 원액이 1 내지 9 중량부로 포함된 것일 수 있다. 예컨대, 크랜베리 용액은 2 내지 8.5 중량부 또는 4 내지 8 중량부로 포함될 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the cranberry solution may contain 1 to 9 parts by weight of the cranberry stock solution relative to 100 parts by weight of the total composition. For example, the cranberry solution may be contained in an amount of 2 to 8.5 parts by weight or 4 to 8 parts by weight, but is not limited thereto.
본 발명에 있어서, 중쇄 지방산은 카프릴산(caprylic acid), 카프릭산(capric acid) 또는 라우르산(lauric acid)일 수 있다. 한 구체예에서, 상기 중쇄 지방산은 카프릴산일 수 있다. In the present invention, the heavy chain fatty acid may be caprylic acid, capric acid or lauric acid. In one embodiment, the heavy chain fatty acid may be caprylic acid.
또한, 에센셜 오일은 타임 티몰(time thymol) 또는 카바크롤(carvacrol)일 수 있다. 한 구체예에서, 상기 에센셜 오일은 타임 티몰일 수 있다. In addition, the essential oil may be time thymol or carvacrol. In one embodiment, the essential oil may be timothymol.
상기 중쇄 지방산과 에센셜 오일은 전체 조성물 100 중량부에 대하여 각각 0.001 내지 0.5 중량부로 포함될 수 있으며, 예컨대 0.005 내지 0.099 중량부, 0.01 내지 0.09 중량부 또는 0.02 내지 0.07 중량부로 포함될 수 있으나, 이에 제한되는 것은 아니다.The heavy chain fatty acid and the essential oil may be contained in an amount of 0.001 to 0.5 part by weight, for example, 0.005 to 0.099 part by weight, 0.01 to 0.09 part by weight, or 0.02 to 0.07 part by weight, respectively, based on 100 parts by weight of the total composition. no.
한 구체예에서, 중쇄 지방산과 에센셜 오일은 1:2 내지 2:1의 함량비로 포함되어 조합되는 것일 수 있다.In one embodiment, the heavy chain fatty acid and the essential oil may be combined and included in a ratio of 1: 2 to 2: 1.
다른 구체예에서, 크랜베리 용액과 중쇄 지방산; 및 크랜베리 용액과 에센셜 오일은 각각 10:1 내지 35:1의 함량비, 예를 들어 12:1 내지 20:1, 13:1 내지 18:1, 14:1 내지 17:1, 21:1 내지 35:1, 25:1 내지 34:1, 30:1 내지 33:1의 함량비일 수 있으며, 보다 구체적으로 14:1 내지 17:1 또는 30:1 내지 33:1의 함량비로 포함되어 조합되는 것일 수 있다.In another embodiment, a cranberry solution and a medium chain fatty acid; And the cranberry solution and the essential oil may be used in a ratio of 10: 1 to 35: 1, for example 12: 1 to 20: 1, 13: 1 to 18: 1, 14: 1 to 17: May be contained in a ratio of 35: 1, 25: 1 to 34: 1, 30: 1 to 33: 1, more specifically in a content ratio of 14: 1 to 17: 1 or 30: Lt; / RTI >
본 발명에 있어서, 상기 조성물의 조성물 총 중량에 대한 함량은 본 발명의 조성물이 적용되는 대상체에 따라 변할 수 있다.In the present invention, the content of the composition relative to the total weight of the composition may vary depending on the object to which the composition of the present invention is applied.
한편, 본 명세서에서 용어 '유효성분으로 포함하는'이란 크랜베리 용액, 중쇄 지방산 및 에센셜 오일의 항균 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. The term " comprising as an active ingredient ", on the other hand, means an amount sufficient to achieve the antimicrobial activity or activity of the cranberry solution, the heavy chain fatty acid and the essential oil.
상기 크랜베리 용액, 중쇄 지방산 및 에센셜 오일은 천연물로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 상기 성분들의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.Since the cranberry solution, the heavy chain fatty acid and the essential oil have no adverse effects on the human body even when administered in an excessive amount as a natural product, the quantitative upper limit of the components contained in the composition of the present invention can be selected by a person skilled in the art within a suitable range.
또한, 본 발명은 상기 항균용 조성물을 포함하는 요로병원성 대장균에 의해 형성되는 바이오필름을 제거하기 위한 조성물, 요로감염증의 예방 또는 치료용 약학 조성물, 요로감염증의 예방 또는 개선용 식품 조성물, 사료 또는 사료 첨가제 조성물, 위생용품 및 상기 조성물을 이용한 요로병원성 대장균의 활성 억제 방법을 제공한다.The present invention also relates to a composition for removing biofilm formed by a pathogenic Escherichia coli comprising the above antimicrobial composition, a pharmaceutical composition for preventing or treating urinary tract infections, a food composition for preventing or improving urinary tract infections, An additive composition, a sanitary article, and a method for inhibiting the activity of urinary pathogenic Escherichia coli using the composition.
본 발명에 따른 항균용 조성물이 약학 조성물로 사용되는 경우, 상기 약학 조성물은 요로감염증 예방 또는 치료를 위하여 포함되는 상기 유효성분 이외에, 추가로 동일 또는 유사한 기능을 가지는 유효성분을 1종 이상 포함할 수 있다. 예컨대, 요로감염증의 예방 또는 치료에 효과가 있는 공지의 요로감염증 치료제 등을 더 포함할 수 있다. 추가적인 성분을 포함하게 되면 본 발명의 조성물의 요로감염증에 대한 예방 또는 치료 효과는 더욱 증진될 수 있다. 상기 성분 추가시에는 복합 사용에 따른 안정성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 상기 추가의 성분은 전체 조성물 중량에 대하여, 0.0001 중량부 이상 내지 10 중량부 이하로 포함될 수 있다. 예를 들어, 0.0001 중량부 이상 내지 1 중량부 이하, 0.0001 중량부 이상 내지 0.1 중량부 이하, 0.0001 중량부 이상 내지 0.001 중량부 이하, 0.001 중량부 이상 내지 10 중량부 이하, 0.001 중량부 이상 내지 1 중량부 이하, 0.001 중량부 이상 내지 0.1 중량부 이하, 0.01 중량부 이상 내지 10 중량부 이하, 0.01 중량부 이상 내지 1 중량부 이하일 수 있다.When the antimicrobial composition according to the present invention is used as a pharmaceutical composition, the pharmaceutical composition may contain one or more active ingredients having the same or similar functions in addition to the above-mentioned effective ingredients for preventing or treating urinary tract infections have. For example, a known therapeutic agent for urinary tract infections, which is effective for preventing or treating urinary tract infections. When the composition contains an additional ingredient, the effect of preventing or treating urinary tract infections of the composition of the present invention can be further enhanced. When the above components are added, stability in combination use, easiness in formulation, and stability of effective ingredients can be considered. The additional component may be included in an amount of 0.0001 part by weight to 10 parts by weight based on the total weight of the composition. For example, 0.0001 part by weight or more and 1 part by weight or less, 0.0001 part by weight or more and 0.1 part by weight or less, 0.0001 parts by weight or more and 0.001 parts by weight or less, 0.001 parts by weight or more and 10 parts by weight or less, 0.001 parts by weight or more and 0.1 parts by weight or less, 0.01 parts by weight or more and 10 parts by weight or less, and 0.01 parts by weight or more and 1 part by weight or less.
본 발명의 약학 조성물은 인간을 비롯한 포유동물에 어떠한 방법으로도 투여할 수 있다. 예를 들어, 경구 또는 비경구로 투여할 수 있으며, 바람직하게는 경구 투여일 수 있고, 비경구적인 투여방법으로는 이에 제한되는 것은 아니나, 정맥내, 근육내, 동맥내, 골수내, 경막내, 심장내, 경피, 피하, 복강내, 비강내, 장관, 국소, 설하 또는 직장 내 투여일 수 있다.The pharmaceutical composition of the present invention can be administered to mammals including humans by any method. For example, it can be administered orally or parenterally, preferably orally, and parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, Transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal administration.
본 발명의 약학 조성물은 상술한 바와 같은 투여 경로에 따라 경구 투여용 또는 비경구 투여용 제제로 제형화 할 수 있다. 제형화할 경우에는 하나 이상의 완충제(예를 들어, 식염수 또는 PBS), 카보하이드레이트(예를 들어, 글루코스, 만노스, 수크로스, 또는 덱스트란 등), 항산화제, 정균제, 킬레이트화제(예를 들어, EDTA 또는 글루타치온), 충진제, 증량제, 결합제, 아쥬반트(예를 들어, 알루미늄 하이드록사이드), 현탁제, 농후제 습윤제, 붕해제 또는 계면활성제, 희석제 또는 부형제를 사용하여 조제될 수 있다.The pharmaceutical composition of the present invention may be formulated into oral or parenteral dosage forms according to the route of administration as described above. When formulated, one or more buffers (e. G., Saline or PBS), carbohydrates (e. G., Glucose, mannose, sucrose or dextran), antioxidants, bacteriostats, chelating agents Diluents or excipients such as suspending agents, diluents or glutathione), fillers, extenders, binders, adjuvants (e.g., aluminum hydroxides), suspending agents, thickening agents, disintegrating or surfactants, diluents or excipients.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 액제, 겔제, 시럽제, 슬러리제, 현탁액 또는 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 약제학적 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분(옥수수 전분, 밀 전분, 쌀 전분, 감자 전분 등 포함), 칼슘카보네이트(Calcium carbonate), 수크로스(Sucrose), 락토오스(Lactose), 덱스트로오스, 솔비톨, 만니톨, 자일리톨, 에리스리톨 말티톨, 셀룰로즈, 메틸 셀룰로즈, 나트륨 카르복시메틸셀룰로오즈 및 하이드록시프로필메틸-셀룰로즈 또는 젤라틴 등을 섞어 조제될 수 있다. 예컨대, 활성성분을 고체 부형제와 배합한 다음 이를 분쇄하고 적합한 보조제를 첨가한 후 과립 혼합물로 가공함으로써 정제 또는 당의정제를 수득할 수 있다. Solid formulations for oral administration include tablets, pills, powders, granules, solutions, gels, syrups, slurries, suspensions or capsules, which may contain at least one excipient in the pharmaceutical composition of the present invention (Including corn starch, wheat starch, rice starch, potato starch and the like), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol maltitol, Cellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethyl-cellulose or gelatin. For example, tablets or tablets may be obtained by combining the active ingredient with a solid excipient, then milling it, adding suitable auxiliaries, and processing the mixture into granules.
단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제 또는 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물 또는 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제 또는 보존제 등이 포함될 수 있다.In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions or syrups. In addition to water or liquid paraffin, which is a simple diluent commonly used, various excipients such as wetting agents, sweeteners, fragrances or preservatives may be included .
또한, 경우에 따라 가교결합 폴리비닐피롤리돈, 한천, 알긴산 또는 나트륨 알기네이트 등을 붕해제로 첨가할 수 있으며, 항응집제, 윤활제, 습윤제, 향료, 유화제 및 방부제 등을 추가로 포함할 수 있다.In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may optionally be added as a disintegrant, and may further include an anticoagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent .
비경구적으로 투여하는 경우 본 발명의 약학 조성물은 적합한 비경구용 담체와 함께 주사제, 경피 투여제 및 비강 흡입제의 형태로 당 업계에 공지된 방법에 따라 제형화될 수 있다. 상기 주사제의 경우에는 반드시 멸균되어야 하며 박테리아 및 진균과 같은 미생물의 오염으로부터 보호되어야 한다. 주사제의 경우 적합한 담체의 예로는 이에 한정되지는 않으나, 물, 에탄올, 폴리올(예를 들어, 글리세롤, 프로필렌 글리콜 및 액체 폴리에틸렌 글리콜 등), 이들의 혼합물 및/또는 식물유를 포함하는 용매 또는 분산매질일 수 있다. 보다 바람직하게는, 적합한 담체로는 행크스 용액, 링거 용액, 트리에탄올 아민이 함유된 PBS(phosphate buffered saline) 또는 주사용 멸균수, 10% 에탄올, 40% 프로필렌 글리콜 및 5% 덱스트로즈와 같은 등장 용액 등을 사용할 수 있다. 상기 주사제를 미생물 오염으로부터 보호하기 위해서는 파라벤, 클로로부탄올, 페놀, 소르빈산, 티메로살 등과 같은 다양한 항균제 및 항진균제를 추가로 포함할 수 있다. 또한, 상기 주사제는 대부분의 경우 당 또는 나트륨 클로라이드와 같은 등장화제를 추가로 포함할 수 있다.For parenteral administration, the pharmaceutical compositions of the present invention may be formulated in accordance with methods known in the art in the form of injectable, transdermal and nasal inhalers, together with suitable non-oral carriers. In the case of such injections, they must be sterilized and protected against contamination of microorganisms such as bacteria and fungi. Examples of suitable carriers for injectables include, but are not limited to, solvents or dispersion media containing water, ethanol, polyols (e.g., glycerol, propylene glycol and liquid polyethylene glycol, etc.), mixtures thereof and / or vegetable oils . More preferably, suitable carriers include isotonic solutions such as Hanks' solution, Ringer's solution, phosphate buffered saline (PBS) containing triethanolamine, or sterile water for injection, 10% ethanol, 40% propylene glycol and 5% dextrose Etc. may be used. In order to protect the injection from microbial contamination, various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like may be further included. In addition, the injections may in most cases additionally include isotonic agents, such as sugars or sodium chloride.
경피 투여제의 경우 연고제, 크림제, 로션제, 겔제, 외용액제, 파스타제, 리니멘트제, 에어롤제 등의 형태가 포함된다. 상기에서 '경피 투여'는 약제학적 조성물을 국소적으로 피부에 투여하여 약제학적 조성물에 함유된 유효한 양의 활성성분이 피부 내로 전달되는 것을 의미한다. Examples of transdermal dosage forms include ointments, creams, lotions, gels, solutions for external use, pastes, liniments, and air lozenges. By " transdermal administration " as used herein, it is meant that the pharmaceutical composition is locally administered to the skin, whereby an effective amount of the active ingredient contained in the pharmaceutical composition is delivered into the skin.
흡입 투여제의 경우, 본 발명에 따라 사용되는 화합물은 적합한 추진제, 예를 들면, 디클로로플루오로메탄, 트리클로로플루오로메탄, 디클로로테트라플루오로에탄, 이산화탄소 또는 다른 적합한 기체를 사용하여, 가압 팩 또는 연무기로부터 에어로졸 스프레이 형태로 편리하게 전달 할 수 있다. 가압 에어로졸의 경우, 투약 단위는 계량된 양을 전달하는 밸브를 제공하여 결정할 수 있다. 예를 들면, 흡입기 또는 취입기에 사용되는 젤라틴 캡슐 및 카트리지는 화합물, 및 락토오스 또는 전분과 같은 적합한 분말 기제의 분말 혼합물을 함유하도록 제형화할 수 있다. 비경구 투여용 제형은 모든 제약 화학에 일반적으로 공지된 처방서인 문헌(Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour)에 기재되어 있다.In the case of an inhalation dosage form, the compounds used according to the invention can be formulated into a pressurized pack or a pressurized pack using a suitable propellant, for example dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gases. It can be conveniently delivered in the form of an aerosol spray from a nebulizer. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve that delivers a metered amount. For example, gelatin capsules and cartridges used in inhalers or insufflators may be formulated to contain the compound and a powder mixture of suitable powder base such as lactose or starch. Formulations for parenteral administration are described in Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, commonly known in all pharmaceutical chemistries.
본 발명의 약학 조성물의 총 유효량은 단일 투여량(single dose)으로 환자에게 투여될 수 있으며, 다중 투여량(multiple dose)으로 장기간 투여되는 분할 치료 방법(fractionated treatment protocol)에 의해 투여될 수 있다. 본 발명의 약학 조성물은 질환의 정도에 따라 유효성분의 함량을 달리할 수 있다. 상기 크랜베리 용액, 중쇄 지방산 및 에센셜 오일의 용량은 약학 조성물의 투여 경로 및 치료 횟수뿐만 아니라 환자의 연령, 체중, 건강 상태, 성별, 질환의 중증도, 식이 및 배설율 등 다양한 요인들을 고려하여 환자에 대한 적절한 유효 투여량을 결정할 수 있을 것이다. 본 발명에 따른 약학 조성물은 본 발명의 효과를 보이는 한 그 제형, 투여 경로 및 투여 방법에 특별히 제한되지 아니한다.The total effective amount of the pharmaceutical composition of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol administered over a prolonged period of time in multiple doses. The pharmaceutical composition of the present invention may vary in the content of the active ingredient depending on the degree of the disease. The dose of the cranberry solution, the heavy chain fatty acid and the essential oil may be determined by taking into consideration various factors such as the route of administration and the number of treatments of the pharmaceutical composition as well as the patient's age, body weight, health condition, sex, severity of disease, A suitable effective dose will be determined. The pharmaceutical composition according to the present invention is not particularly limited to the formulation, administration route and administration method as long as the effect of the present invention is exhibited.
본 발명의 약학 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 또는 생물학적 반응조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The pharmaceutical compositions of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy or biological response modifiers.
본 발명의 조성물이 식품 조성물로 사용되는 경우, 식품 조성물은 상기 약학 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 알코올 음료류, 과자류, 다이어트바, 유제품, 육류, 초코렛, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 비타민 복합제, 건강보조식품류 등이 있다.When the composition of the present invention is used as a food composition, the food composition may be formulated in the same manner as the above-described pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectioneries, diet bars, dairy products, meat, chocolates, pizza, ram noodles, other noodles, gums, ice cream, .
본 발명의 식품 조성물은 유효성분으로서 크랜베리 용액, 중쇄 지방산 및 에센셜 오일뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 본 발명의 상기 유효성분 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention may contain, as an active ingredient, cranberry solution, medium chain fatty acid and essential oil, as well as components that are conventionally added in the manufacture of food, such as proteins, carbohydrates, fats, nutrients, And flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is prepared from a drink and a beverage, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, various plant extracts and the like may be further added in addition to the above- .
본 발명은 크랜베리 용액, 중쇄 지방산으로서 카프릴산 및 에센셜 오일로서 타임 티몰을 유효성분으로 포함하는 요로감염증의 예방 및 개선용 식품 조성물을 포함하는 건강기능식품을 제공한다. 건강기능식품이란, 상기 크랜베리 용액, 중쇄 지방산 및 에센셜 오일을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 크랜베리 용액, 중쇄 지방산 및 에센셜 오일의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량부, 바람직하기로는 0.1 내지 20 중량부의 범위이다. 또한, 환제, 과립제, 정제 또는 캡슐제 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량부 바람직하기로는 0.5 내지 80 중량부의 범위에서 첨가하면 된다. 한 구체예에서, 본 발명의 건강기능식품은 환제, 정제, 캡슐제 또는 음료의 형태일 수 있다.The present invention provides a health functional food comprising a cranberry solution, caprylic acid as a medium-chain fatty acid, and a food composition for preventing and improving urinary tract infections including timothymol as an active ingredient as an essential oil. The health functional food refers to a food prepared by adding the above cranberry solution, heavy chain fatty acid and essential oil to a food material such as beverage, tea, spice, gum or confection, or encapsulating, powdering or suspending, But it has the advantage that there are no side effects that can occur when a drug is used for a long period of time using a food as a raw material. The health functional food of the present invention thus obtained is very useful because it can be ingested routinely. The amount of the cranberry solution, the heavy chain fatty acid and the essential oil added in such a health functional food can not be uniformly determined depending on the kind of the health functional food to be added, but may be added within a range that does not deteriorate the original taste of the food, Is usually in the range of 0.01 to 50 parts by weight, preferably 0.1 to 20 parts by weight, based on the target food. In the case of health functional foods in the form of pills, granules, tablets or capsules, they may be added in an amount of usually 0.1 to 100 parts by weight, preferably 0.5 to 80 parts by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.
상기 항균용 조성물을 사료 또는 사료 첨가제 조성물로 사용하는 경우, 상기 조성물은 20 내지 90% 고농축액이거나 분말 또는 과립 형태로 제조될 수 있다. 상기 사료첨가제는 구연산, 후말산, 아디픽산, 젖산, 사과산등의 유기산이나 인산 나트륨, 인산 칼륨, 산성 피로인산염, 폴리인산염(중합인산염) 등의 인산염이나, 폴리페놀, 카테킨, 알파-토코페롤, 로즈마리 추출물, 비타민 C, 녹차 추출물, 감초 추출물, 키토산, 탄닌산, 피틴산 등의 천연 항산화제 중 어느 하나 또는 하나 이상을 추가로 포함할 수 있다. 사료로서 이용될 경우, 상기 조성물은 통상의 사료 형태로 제제화 될 수 있으며, 통상의 사료성분을 함께 포함할 수 있다.When the antimicrobial composition is used as a feed or feed additive composition, the composition may be 20 to 90% high concentrate, or may be prepared in powder or granular form. The feed additive may be selected from the group consisting of organic acids such as citric acid, fumaric acid, adipic acid, lactic acid and malic acid, phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate (polymerized phosphate), polyphenol, catechin, alpha-tocopherol, Extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, phytic acid, and the like. When used as a feed, the composition may be formulated in conventional feed form and may contain conventional feed ingredients.
상기 사료첨가제 및 사료는 곡물, 예를 들면 분쇄 또는 파쇄된 밀, 귀리, 보리, 옥수수 및 쌀; 식물성 단백질 사료, 예를 들면 평지, 콩, 및 해바라기를 주성분으로 하는 사료; 동물성 단백질 사료, 예를 들면 혈분, 육분, 골분 및 생선분; 당분 및 유제품, 예를 들면 각종 분유 및 유장 분말로 이루어지는 건조성분 등을 더 포함할 수 있으며, 이외에도 영양보충제, 소화 및 흡수향상제, 성장촉진제 등을 더 포함할 수 있다.The feed additives and feeds may be selected from the group consisting of cereals, such as ground or crushed wheat, oats, barley, corn and rice; Feeds based on vegetable protein such as rapeseed, soybeans and sunflower; Animal protein feeds such as blood, meat, bone meal and fish meal; A sugar or a milk product, for example, a dry component comprising various powdered milk and whey powder, and may further include nutritional supplements, digestion and absorption enhancers, growth promoters, and the like.
상기 사료첨가제는 동물에게 단독으로 투여하거나 식용 담체 중에서 다른 사료첨가제와 조합하여 투여할 수도 있다. 또한, 상기 사료첨가제는 탑드레싱으로서 또는 이들을 동물사료에 직접 혼합하거나 또는 사료와 별도의 경구제형으로 용이하게 동물에게 투여할 수 있다. 상기 사료첨가제를 동물사료와 별도로 투여할 경우, 당해 기술분야에 잘 알려진 바와 같이 약제학적으로 허용가능한 식용 담체와 조합하여, 즉시 방출 또는 서방성 제형으로 제조할 수 있다. 이러한 식용 담체는 고체 또는 액체, 예를 들어 옥수수전분, 락토오스, 수크로오스, 콩플레이크, 땅콩유, 올리브유, 참깨유 및 프로필렌글리콜일 수 있다. 고체 담체가 사용될 경우, 사료첨가제는 정제, 캡슐제, 산제, 트로키제 또는 함당정제 또는 미분산성 형태의 탑 드레싱일 수 있다. 액체 담체가 사용될 경우, 사료첨가제는 젤라틴 연질 캡슐제, 또는 시럽제나 현탁액, 에멀젼제, 또는 용액제의 제형일 수 있다.The feed additive may be administered to animals singly or in combination with other feed additives in edible carriers. The feed additives can also be administered to the animal either as a top dressing or they can be mixed directly with the animal feed or in a separate oral form separate from the feed. When the feed additive is administered separately from an animal feed, it can be prepared in an immediate release or sustained release formulation, in combination with a pharmaceutically acceptable edible carrier as is well known in the art. Such edible carriers may be solid or liquid, such as corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol. When a solid carrier is used, the feed additive can be a tablet, capsule, powder, troche or emulsion or top-dressing in finely divided form. When a liquid carrier is used, the feed additive can be a gelatin soft capsule, or a syrup or suspension, emulsion, or solution formulation.
상기 사료는 동물의 식이욕구를 충족시키는데 통상적으로 사용되는 임의의 단백질-함유 유기곡분을 포함할 수 있다. 이러한 단백질-함유 곡분은 통상적으로 옥수수, 콩곡분, 또는 옥수수/콩곡분믹스로 주로 구성되어 있다.The feed may comprise any protein-containing organic fructose commonly used to meet an animal's dietary needs. These protein-containing flours usually consist mainly of corn, soy flour, or corn / soy flour mix.
또한, 상기 사료첨가제 및 사료는 보조제, 예를 들어 보존제, 안정화제, 습윤제 또는 유화제, 용액촉진제 등을 함유할 수 있다. 상기 사료첨가제는 침주, 분무 또는 혼합하여 동물의 사료에 첨가하여 이용될 수 있다.The feed additives and feeds may also contain adjuvants such as preservatives, stabilizers, wetting or emulsifying agents, solution promoters and the like. The feed additive may be used by adding to the animal's feed by pouring, spraying or mixing.
본 발명의 사료 또는 사료첨가제는 포유류를 포함하는 다수의 동물식이에 적용할 수 있다.The feed or feed additive of the present invention can be applied to a large number of animal diets including mammals.
상기 포유류로서 돼지, 소, 양, 염소, 실험용 설치동물, 및 실험용 설치동물뿐만 아니라, 애완동물(예: 개, 고양이) 등에게 사용할 수 있으며, 이에 제한되는 것은 아니나 요로감염성 대장균으로부터 요로감염증이 유발될 수 있는 동물이라면 모두 적용할 수 있다.Such mammals include but are not limited to pigs, cows, sheep, goats, laboratory animals and laboratory animals as well as pets (e.g. dogs and cats), including but not limited to urinary tract infections from urinary tract infections Any animal that can be used can be applied.
또한, 본 발명에 따른 항균용 조성물은 이를 위생용품 소재가 되는 섬유 시트에 처리하여 항균 시트를 제조하는 단계를 포함함으로써 요로병원성 대장균의 항균용 위생용품을 제조할 수 있다. 상기 위생용품으로는 여성 위생용품을 포함할 수 있다. 상기 여성 위생용품은 인체 분비액, 예컨대 생리액을 흡수하도록 구성된 광범위한 범위의 각종 흡수용품 등일 수 있으며, 질 세정제와 같은 세척용품일 수 있다. 구체적으로, 외음부 영역 주변의 외부 착용을 위해 개발된 생리대와 팬티라이너, 질강 내 또는 세정제에 배치되어 질강으로부터의 생리 흐름을 질전정 도달 전에 차단하도록 개발된 탐폰, 기저귀, 콘돔 등일 수 있으나, 이에 제한되는 것은 아니다. 본 발명에 따른 조성물은 상기 여성 위생용품 외에도 요로감염증을 예방하기 위한 세정제, 세척제 등에도 적용할 수 있다. 위생용품에 본 발명의 조성물이 처리되는 경우, 요로감염증의 예방 또는 개선 효과를 나타낼 수 있다.The antimicrobial composition according to the present invention may further comprise a step of treating the fibrous sheet as a sanitary article to prepare an antimicrobial sheet, thereby producing an antibacterial sanitary article of Escherichia coli. Such sanitary articles may include feminine hygiene articles. The feminine hygiene article may be a wide range of various absorbent articles configured to absorb human body fluid, e.g., a physiological fluid, and may be a cleaning article, such as a vaginal detergent. Specifically, it may be a sanitary napkin and a panty liner developed for external wear around the vulva region, a tampon, a diaper, a condom, or the like, which is disposed in the vagina or the detergent and developed to block the menstrual flow from the vagina before reaching the vagina. It is not. The composition according to the present invention can be applied not only to feminine hygiene products but also to detergents and cleaning agents for preventing urinary tract infections. When the composition of the present invention is treated in a sanitary article, it may exhibit an effect of preventing or improving urinary tract infections.
상기 위생용품을 제조함에 있어서, 본 발명의 조성물의 처리 시간, 처리 온도 등의 조건은 당업자가 적의적절하게 적용시킬 수 있다.In manufacturing the sanitary article, the conditions such as the treatment time and the treatment temperature of the composition of the present invention can be suitably applied by those skilled in the art.
또한, 본 발명은 상기 항균용 조성물을 인간을 제외한 생물체 또는 비생물체의 표면에 처리하는 단계를 포함하는 요로병원성 대장균의 활성 억제 방법을 제공한다.The present invention also provides a method of inhibiting the activity of urinary pathogenic Escherichia coli comprising the step of treating the above-mentioned antimicrobial composition on the surface of an organism or an organism other than human.
본 발명에 있어서, 상기 생물체는 인간을 제외한 동물이며, 예컨대 포유류로서 돼지, 소, 양, 염소, 실험용 설치동물, 및 실험용 설치동물뿐만 아니라, 애완동물(예: 개, 고양이) 등에게 사용할 수 있으며, 이에 제한되는 것은 아니나 요로감염성 대장균으로부터 요로감염증이 유발될 수 있는 동물이라면 모두 적용할 수 있다. 또한, 비생물체로는 상기 항균용 조성물을 처리할 수 있는 표면을 가진 것이라면 종류가 제한되는 것은 아니다. 예컨대 위생용품의 소재가 되는 섬유 시트 등을 포함할 수 있다.In the present invention, the organism is an animal other than a human. For example, it can be used for a mammal such as a pig, a cattle, a sheep, a goat, a laboratory animal, and a laboratory animal as well as a pet , But not limited to, any animal capable of inducing urinary tract infection from urinary tract infectious E. coli. The type of the non-living matter is not limited as long as it has a surface capable of treating the above-mentioned antimicrobial composition. For example, a fiber sheet as a material for sanitary articles.
본 발명의 항균용 조성물은 요로감염성 대장균을 효과적으로 저해시킬 수 있을 뿐만 아니라, 크랜베리 용액, 중쇄 지방산 및 에센셜 오일을 조합함으로써 얻을 수 있는 항균 시너지로 인해 개별적으로 사용되는 각 성분들의 양을 최소화함으로써 적은 양으로도 요로감염증을 예방, 개선 및 치료할 수 있으며, 개별적인 성분들의 사용량 감소로 인한 비용 절감의 효과도 함께 얻을 수 있다.The antimicrobial composition of the present invention not only effectively inhibits urinary tract infectious Escherichia coli but also minimizes the amount of each ingredient individually used due to the antibacterial synergy that can be obtained by combining cranberry solution, heavy chain fatty acid and essential oil, Can also prevent, ameliorate, and treat urinary tract infections, and can also reduce the cost by reducing the amount of individual components used.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어 있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described in detail below. The present invention may, however, be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Is provided to fully convey the scope of the invention to those skilled in the art, and the invention is only defined by the scope of the claims.
[제조예 1] 항균 대상 균주의 배양 및 바이오필름이 형성된 인공요로의 제조[Preparation Example 1] Cultivation of a strain to be subjected to antibacterial activity and production of artificial urinary tract in which a biofilm was formed
요로감염 원인의 80% 이상을 차지하는 요로감염대장균(Uropathogenic E. coli)의 두 strain인 E. coli AMG1(stanford isolate)과 E. coli ATCC 11775를 실험대상 균주로 선정하였다. 요로 환경의 재현을 위해 인공소변배지에 상기 균주를 분주하여 37℃에서 24시간 동안 배양하였다. 배양한 각 균주는 50ml 플라스틱 튜브에 혼합한 후, 3,000g에서 15분간 원심분리 하였고 상등액을 따라낸 뒤 동량의 0.85% 멸균 생리식염수를 첨가하여 미생물 세포를 2회 세척함으로써 균액을 제조하였다. Both the strain of E. coli urinary tract infections account for more than 80% of urinary tract infections caused (Uropathogenic E. Coli) E. E. coli AMG1 (stanford isolate) and E. E. coli ATCC 11775 was selected as the strain to be tested. In order to reproduce the urinary tract environment, the above strain was dispensed into an artificial urine culture and cultured at 37 ° C for 24 hours. Each strain was mixed with 50 ml plastic tube, centrifuged at 3,000 g for 15 minutes, poured over the supernatant, and the same amount of 0.85% sterilized physiological saline was added to wash the microbial cells twice to prepare a broth.
바이오필름을 형성시키는 표면의 경우에도 요로환경을 재현하기 위하여 인공 도뇨관(catheter)의 재료로 이용되는 실리콘 판을 잘라 실리콘 쿠폰형태의 인공요로를 제작한 뒤 멸균하여 이용하였다. 요로감염대장균 바이오필름은 균액을 인공소변배지에 접종한 후 이에 실리콘 쿠폰(인공요로)을 넣은 뒤 48시간마다 인공소변배지를 교체하며 7일 동안 형성시켰다. 7일 후 실리콘 쿠폰(인공요로)에 형성된 바이오필름은 멸균 증류수를 이용하여 느슨하게 부착된 균을 제거한 뒤 실험에 사용하였다.In order to reproduce the urinary environment, a silicon plate used as an artificial catheter material was cut to form a silicone coupon-shaped artificial urine, and then sterilized. Urinary tract infection Escherichia coli Biofilm was formed for 7 days after inoculating the bacterial solution into the artificial urine culture medium, replacing the artificial urine culture medium every 48 hours after inserting the silicone coupon (artificial urinary tract). After 7 days, the biofilm formed in the silicone coupon (artificial urinary tract) was sterilized using distilled water to remove loosely adhered bacteria and then used in the experiment.
[실시예 1 내지 8 및 비교예 1 내지 19] 항균용 조성물의 제조 [Examples 1 to 8 and Comparative Examples 1 to 19] Preparation of antimicrobial composition
크랜베리 원액(Cranberry Juice Concentrate, Dynamic Health Laboratories, Inc., USA)을 물에 희석하여 크랜베리가 4 중량부 및 8 중량부로 포함되는 크랜베리 용액을 준비하였다. 다음으로, 98% 에탄올을 이용하여 카프릴산(Sigma Chemical co., St. Louis, MO, USA) 및 타임 티몰(Sigma-Aldrich, St. Louis, MO, USA)을 각각 2.5 중량부 및 5 중량부를 포함하는 표준 용액을 각각 준비하였다. 크랜베리 용액이 9.8 ml씩 담겨있는 멸균 튜브에 각 실험군에 해당하는 농도의 카프릴산과 타임 티몰의 표준 용액을 0.1 ml씩 첨가하고 균질화하여 최종적으로 아래 표 1과 같은 조성의 항균용 조성물을 제조하였다. 제조를 마친 조성물은 37℃로 설정된 교반 항온수조에서 예열하였다.Cranberry juice concentrate (Dynamic Health Laboratories, Inc., USA) was diluted in water to prepare a cranberry solution containing 4 parts by weight and 8 parts by weight of cranberry. 2.5 parts by weight of caprylic acid (Sigma Chemical Co., St. Louis, Mo., USA) and time thymol (Sigma-Aldrich, St. Louis, Mo., USA) Were prepared. 0.1 ml of a standard solution of caprylic acid and time-thymol corresponding to each experimental group was added to a sterilized tube containing 9.8 ml of cranberry solution and homogenized to prepare an antimicrobial composition having the composition shown in Table 1 below. The prepared composition was preheated in a stirred constant temperature water bath set at 37 占 폚.
[[ 실험예Experimental Example 1] 요로감염대장균에 대한 항균 시너지 효과 확인 1] Identification of antimicrobial synergy against E. coli
본 발명에 따른 항균용 조성물의 요로감염대장균 바이오필름을 대상으로 항균 시너지 효과를 확인하기 위해, 본 발명의 항균용 조성물에 5 내지 6 log CFU/coupon 수준의 바이오필름이 형성된 실리콘 쿠폰을 넣고 37℃의 교반 항온수조에서 1분간 처리한 후, DE buffer(Dey/Engley neutralizing buffer)에 실리콘쿠폰을 넣어 항균 효과를 종결시켰다. 처리를 마친 후 실리콘쿠폰에 남아있는 바이오필름을 탈착시키기 위하여 초음파처리(sonication)를 이용하였고, 탈착된 바이오필름은 희석한 뒤 증균배지에 도말하였다. 도말한 배지는 37℃에서 24시간 배양한 후 배지 상에 형성된 콜로니 수를 계수하여 각 조건별 균 저감화 값을 log 값으로 산출하였다. 모든 실험은 3회 반복 수행하였으며, 그 결과는 아래 표 2와 같다.In order to confirm the antibiotic synergistic effect of the antibiotic-resistant E. coli biofilm of the antimicrobial composition according to the present invention, a silicone coupon having a biofilm of 5-6 log CFU / coupon level was added to the antimicrobial composition of the present invention, , And the antimicrobial effect was terminated by adding a silicone coupon to DE buffer (Dey / Engley neutralizing buffer). After the treatment, sonication was used to desorb the remaining biofilm in the silicone coupon, and the desorbed biofilm was diluted and plated on the supernatant. The cultured medium was cultured at 37 ° C for 24 hours, and the number of colonies formed on the medium was counted, and the value of the bacterial reduction by each condition was calculated as a log value. All experiments were repeated three times, and the results are shown in Table 2 below.
(중량부)Caprylic acid
(Parts by weight)
0.2 ± 0.3(Comparative Example 1)
0.2 ± 0.3
0.4 ± 0.3(Comparative Example 2)
0.4 ± 0.3
0.7 ± 0.2(Comparative Example 3)
0.7 ± 0.2
0.4 ± 0.6(Comparative Example 4)
0.4 ± 0.6
0.6 ± 0.2(Comparative Example 5)
0.6 ± 0.2
2.2 ± 0.3(Comparative Example 6)
2.2 ± 0.3
0.2 ± 0.3(Comparative Example 7)
0.2 ± 0.3
1.4 ± 0.6(Comparative Example 8)
1.4 ± 0.6
2.0 ± 0.3(Comparative Example 9)
2.0 ± 0.3
0.2 ± 0.3(Comparative Example 10)
0.2 ± 0.3
1.1 ± 0.6(Comparative Example 11)
1.1 ± 0.6
2.7 ± 0.6(Comparative Example 12)
2.7 ± 0.6
0.8 ± 0.6(Comparative Example 13)
0.8 ± 0.6
3.3 ± 0.53.3 ± 0.5
4.4 ± 0.64.4 ± 0.6
2.6 ± 0.3(Comparative Example 14)
2.6 ± 0.3
3.4 ± 0.73.4 ± 0.7
4.1 ± 0.74.1 ± 0.7
0.4 ± 0.3(Comparative Example 15)
0.4 ± 0.3
0.1 ± 0.1(Comparative Example 16)
0.1 ± 0.1
3.0 ± 0.6(Comparative Example 17)
3.0 ± 0.6
1.3 ± 0.3(Comparative Example 18)
1.3 ± 0.3
4.0 ± 0.64.0 ± 0.6
4.8 ± 0.94.8 ± 0.9
4.0 ± 1.1(Comparative Example 19)
4.0 ± 1.1
3.7 ± 1.23.7 ± 1.2
5.8 ± 0.1 (ND)5.8 ± 0.1 (ND)
표 2에서 보는 바와 같이, 크랜베리 용액, 카프릴산, 타임 티몰을 모두 함유하는 경우가, 이들을 단독 또는 2종 함유하는 경우보다 바이오필름 저감화 효과가 우수한 것을 확인하였다. 이를 통해 크랜베리 용액, 카프릴산, 타임 티몰의 조합에 따른 바이오필름 저감의 상승(시너지) 효과를 확인할 수 있었다.As shown in Table 2, it was confirmed that the case of containing both the cranberry solution, caprylic acid and time thymol was superior to the case of containing the cranberry solution, the caprylic acid and the time-thymol, either alone or in combination with two of them, It was confirmed that the synergy effect of biofilm reduction due to combination of cranberry solution, caprylic acid, and timothymol was confirmed.
Claims (12)
중쇄 지방산으로서 카프릴산; 및
에센셜 오일로서 타임 티몰을 포함하는 요로병원성 대장균의 항균용 조성물.Cranberry solution;
Caprylic acid as a medium chain fatty acid; And
A composition for the antimicrobial use of Escherichia coli, which comprises time thymol as an essential oil.
크랜베리 용액은 전체 조성물 100 중량부 대비 1 내지 9 중량부로 포함되는 항균용 조성물.The method according to claim 1,
Wherein the cranberry solution is contained in an amount of 1 to 9 parts by weight based on 100 parts by weight of the total composition.
중쇄 지방산 및 에센셜 오일은 전체 조성물 100 중량부 대비 각각 0.001 내지 0.5 중량부로 포함되는 항균용 조성물.The method according to claim 1,
Wherein the heavy chain fatty acid and the essential oil are contained in an amount of 0.001 to 0.5 parts by weight based on 100 parts by weight of the total composition.
중쇄 지방산 및 에센셜 오일은 2:1 내지 1:2의 함량비로 포함되는 항균용 조성물.The method according to claim 1,
Wherein the medium chain fatty acid and the essential oil are contained at a content ratio of 2: 1 to 1: 2.
크랜베리 용액과 중쇄 지방산; 및 크랜베리 용액과 에센셜 오일은 각각 10:1 내지 35:1의 함량비로 포함되는 항균용 조성물.The method according to claim 1,
Cranberry solution and medium chain fatty acids; And the cranberry solution and the essential oil are contained at a content ratio of 10: 1 to 35: 1, respectively.
A method for inhibiting the activity of an urethane pathogenic Escherichia coli comprising the step of treating the composition of any one of claims 1 to 5 on the surface of an organism or an organism other than human.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170017341A KR101835263B1 (en) | 2017-02-08 | 2017-02-08 | Composition having antimicrobial activities for prevention and treatment of urinary tract infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170017341A KR101835263B1 (en) | 2017-02-08 | 2017-02-08 | Composition having antimicrobial activities for prevention and treatment of urinary tract infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101835263B1 true KR101835263B1 (en) | 2018-03-06 |
Family
ID=61727341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170017341A KR101835263B1 (en) | 2017-02-08 | 2017-02-08 | Composition having antimicrobial activities for prevention and treatment of urinary tract infection |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101835263B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210114842A (en) * | 2020-03-11 | 2021-09-24 | (주)에이앤바이오 | Composition for preventing urinary tract infection and improving urinary function in cats |
| KR102337950B1 (en) | 2021-06-25 | 2021-12-13 | 주식회사 비피도 | Lactobacillus salivarius HHuMin-U for improvement, prevention or treatment of urinary tract infection and composition comprising the same |
| KR102337951B1 (en) | 2021-06-25 | 2021-12-13 | 주식회사 비피도 | Lactobacillus helveticus GUT10 for improvement, prevention or treatment of urinary tract infection and composition comprising the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015078151A (en) | 2013-10-17 | 2015-04-23 | 国立大学法人名古屋大学 | Urinary tract infection prevention or therapy |
-
2017
- 2017-02-08 KR KR1020170017341A patent/KR101835263B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015078151A (en) | 2013-10-17 | 2015-04-23 | 国立大学法人名古屋大学 | Urinary tract infection prevention or therapy |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210114842A (en) * | 2020-03-11 | 2021-09-24 | (주)에이앤바이오 | Composition for preventing urinary tract infection and improving urinary function in cats |
| KR102450427B1 (en) * | 2020-03-11 | 2022-10-05 | (주)에이앤바이오 | Composition for preventing urinary tract infection and improving urinary function in cats |
| KR102337950B1 (en) | 2021-06-25 | 2021-12-13 | 주식회사 비피도 | Lactobacillus salivarius HHuMin-U for improvement, prevention or treatment of urinary tract infection and composition comprising the same |
| KR102337951B1 (en) | 2021-06-25 | 2021-12-13 | 주식회사 비피도 | Lactobacillus helveticus GUT10 for improvement, prevention or treatment of urinary tract infection and composition comprising the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6672441B2 (en) | Novel Bacillus beresensis CJBV and antibacterial composition containing the same | |
| KR101835263B1 (en) | Composition having antimicrobial activities for prevention and treatment of urinary tract infection | |
| KR102178926B1 (en) | A composition for reinforcing immune function and anti-fatigue comprising fermented placenta and its use | |
| KR101791549B1 (en) | An antibacterial composition comprising the pachyrhizus erosus root bark extract as an effective component | |
| KR20200003993A (en) | Antimicrobial composition comprising the leaf extract of polygonium ticnctorium and use thereof | |
| KR101467698B1 (en) | Anti-microbial composition comprising cynanchi wilfordii radix extract and the use thereof | |
| KR102162143B1 (en) | Composition for preventing, improving or treating the degenerative brain diseases comprising Pediococcus inopinatus WIKIM27 | |
| KR102086166B1 (en) | Antimicrobial composition comprising the extracts of rambutan peel | |
| KR20200113587A (en) | Antimicrobial composition comprising the extract of rodgersia podophylla | |
| Salaheen et al. | Replacement of conventional antimicrobials and preservatives in food production to improve consumer safety and enhance health benefits | |
| KR20150106191A (en) | Antimicrobial composition comprising the extract of cornus officinalis | |
| KR20100114606A (en) | Composition for prevention or treatment of diseases caused by staphylococcus aureus | |
| KR101795115B1 (en) | Anti-tuberculosis composition for treating or preventing tuberculosis comprising gamma-Linolenic acid | |
| KR20100037310A (en) | Liquefied type manufacturing method of health supporting food | |
| KR102158134B1 (en) | Antibacterial composition comprising an extract of schisandra chinesis | |
| KR101911847B1 (en) | Antimicrobial composition comprising organic solvent fractions of arctium lappa root extracts as an effective component | |
| KR20150133351A (en) | Antimicrobial composition comprising flavonol and antibiotic | |
| KR20190111537A (en) | Composition for Improving Bowel Function or Increasing Intestinal Microbes | |
| KR101775223B1 (en) | A composition for treating or preventing tuberculosis comprising Artesunate | |
| KR20220094308A (en) | Pharmaceutical composition for preventing or treating infectious symptoms by pathogenic microorganism comprising Cichorium intybus extract as an active ingredient | |
| KR101429197B1 (en) | Antibacterial Composition Containing Anthriscus sylvestris Extract | |
| KR101798286B1 (en) | A composition for treating or preventing tuberculosis comprising Linolenic acid | |
| KR20190061899A (en) | Novel agar-derived oligosaccharides for inhibiting staphylococci | |
| KR102386077B1 (en) | Antimicrobial composition comprising extract of Melandryum firmum as an active ingredient | |
| KR101763004B1 (en) | Food composition for preventing or treating urinary tract infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |